Retatrutide 10mg

Retatrutide 10mg – GLP-1/GIP/Glucagon Triple Agonist

Retatrutide (LY3437943) is a triple hormone receptor agonist developed by Eli Lilly that simultaneously acts on GLP-1, GIP, and glucagon receptors. In the Phase 3 TRIUMPH-1 clinical trial (May 2026), Retatrutide delivered the strongest published weight-reduction data for any medication to date.

This 10mg vial is suitable for smaller research projects and initial dosage trials.

Mechanism of action

By simultaneously activating three metabolic pathways, Retatrutide exerts a synergistic effect on energy balance, insulin sensitivity, and fat breakdown. In TRIUMPH-1, participants on the 12 mg dose lost on average 28.3 % of their body weight after 80 weeks — in participants with a BMI ≥35 even up to 30.3 % after 104 weeks. Even lower doses showed strong effects: 9 mg → 25.9 %, 4 mg → 19.0 %.

Technical specifications

Storage: Store at −20 °C (long-term); after reconstitution at 4 °C, use within 2–4 weeks. Protect from light and moisture.

Source: Eli Lilly TRIUMPH-1 Phase 3 study, May 2026

Disclaimer: Not intended for human or veterinary use. For laboratory research purposes only. Not for diagnostic or therapeutic purposes.

Reconstitution note 10 mg: This vial size is particularly suitable for shorter test series or as an entry point into a dose escalation protocol, as less substance is used per attempt and the reconstitution solution is used up accordingly faster.

Reconstitution: Example calculation

To achieve a working concentration of 10 mg/ml, reconstitute the 10 mg vial with 1 ml of sterile bacteriostatic water (BAC water). Slowly inject the water along the inside of the vial and gently swirl it instead of shaking it to avoid damaging the peptide structure. Detailed step-by-step instructions can be found in our user manual.

Frequently Asked Questions

How many trials can be prepared with a 10 mg vial?
Depending on the target concentration and dilution step, several sub-amounts for different experimental approaches can be taken from a 10 mg vial.

Is the 10 mg dose suitable for initial test series?
Yes — the smaller vial size reduces substance consumption in initial trials or pilot studies before larger quantities are ordered.

Quality assurance

Each production batch undergoes independent dual testing: HPLC analysis (High Performance Liquid Chromatography) to determine purity and LC-MS analysis (Liquid Chromatography Mass Spectrometry) to definitively verify molecular mass and correct peptide sequence. Only after passing these tests is a batch released.